Puma Exec's Brother Traded On Cancer Drug Info, SEC Says

Law360, New York (December 7, 2017, 4:32 PM EST) -- The U.S. Securities and Exchange Commission on Wednesday filed a suit in Florida federal court accusing the brother of a Puma Biotechnology Inc. executive of reaping $107,000 in illegal profits through insider trading based on conversations between the two related to the development of a cancer drug.

In the complaint, the SEC said Stephen J. Leonard on four occasions bought Puma stock after speaking to his sibling in the weeks ahead of a July 22, 2014, announcement by the company that its cancer drug neratinib was...
To view the full article, register now.